• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Synageva BioPharma

edit

Synageva is a biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics that leverage the unique competitive advantages of their proprietary Synageva Expression Platform (SEPTM).

Recent Milestones

edit

• 
  Synageva BioPharma — Synageva closes $115M public offering (7/13/12)
  Posted 7/13/12 at 5:36pm via masshightech.com
• 
  Synageva BioPharma received $25M in Venture Round funding. (3/21/11)
  Posted 3/21/11 at 6:12pm via masshightech.com
• 
  Synageva BioPharma — landed a $25 million private equity funding to support development of the Lexington biotech’s enzyme replacement therapy, SBC-102 (3/21/11)
  Posted 3/22/11 at 3:15am via masshightech.com
• 
  Synageva BioPharma — has won orphan drug status from the European Medicines Agency (EMA) for its enzyme replacement therapy, SBC-102, to treat Lysosomal Acid Lipase Deficiency (11/9/10)
  Posted 11/10/10 at 4:11am via masshightech.com
• 
  Synageva BioPharma — Synageva moves to Lexington (9/15/10)
  Posted 9/16/10 at 2:33am via masshightech.com
• 
  Synageva BioPharma received $12M in Series F funding. (10/22/09)
  Posted 11/12/09 at 5:36pm via altassets.net
• 
  Synageva BioPharma received $30M in Series F funding. (4/15/09)
  Posted 4/15/09 at 12:39pm via pehub.com
• 
  Synageva BioPharma received $50M in Venture Round funding. (1/1/60)
  Posted 4/15/09 at 12:40pm via pehub.com
• 
  Synageva BioPharma added Sanj K. Patel as President & Chief Executive Officer.
  Posted 3/22/11 at 12:39am
• 
  Went public with stock symbol NASDAQ:GEVA.
  Posted 7/13/12 at 5:35pm
• 
  Synageva BioPharma added Anthony Quinn as Senior Vice President, Chief Medical Officer & Head of Research & Development.
  Posted 3/22/11 at 12:39am
• 
  Synageva BioPharma added Eric Grinstead as Senior Vice President, Commercial and Business Operations.
  Posted 3/22/11 at 12:39am
• 
  Synageva BioPharma added John C. Taylor as Vice President, Corporate Development.
  Posted 3/22/11 at 12:39am

Videos

Screenshots

edit

Above: Home page
Uploaded: 5/13/09

Stock Price

Sources

1. Synageva BioPharma Raises $30 Million (pehub.com) [edit]
2. Synageva BioPharma Raises $30 Million (pehub.com) [edit]
3. Synageva attracts additional $12m to venture funding round (altassets.net) [edit]
4. Synageva finds $25M financing for enzyme treatment (masshightech.com) [edit]
Synageva expands, moves HQ to Lexington (masshightech.com) [edit]
Synageva lands orphan drug status in Europe (masshightech.com) [edit]
Synageva finds $25M financing for enzyme treatment (masshightech.com) [edit]
Synageva closes $115M public offering (masshightech.com) [edit]